Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs.

Nalli AD, Brown LE, Thomas CL, Sayers TJ, Porco JA Jr, Henrich CJ.

Sci Rep. 2018 Nov 30;8(1):17519. doi: 10.1038/s41598-018-35908-0.

2.

Cytotoxic and other withanolides from aeroponically grown Physalis philadelphica.

Xu YM, Wijeratne EMK, Brooks AD, Tewary P, Xuan LJ, Wang WQ, Sayers TJ, Gunatilaka AAL.

Phytochemistry. 2018 Aug;152:174-181. doi: 10.1016/j.phytochem.2018.04.018. Epub 2018 May 21.

PMID:
29775868
3.

Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells.

Xu YM, Wijeratne EMK, Babyak AL, Marks HR, Brooks AD, Tewary P, Xuan LJ, Wang WQ, Sayers TJ, Gunatilaka AAL.

J Nat Prod. 2017 Jul 28;80(7):1981-1991. doi: 10.1021/acs.jnatprod.6b01129. Epub 2017 Jun 15.

PMID:
28617598
4.

17β-Hydroxywithanolides as Sensitizers of Renal Carcinoma Cells to Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) Mediated Apoptosis: Structure-Activity Relationships.

Xu YM, Brooks AD, Wijeratne EM, Henrich CJ, Tewary P, Sayers TJ, Gunatilaka AA.

J Med Chem. 2017 Apr 13;60(7):3039-3051. doi: 10.1021/acs.jmedchem.7b00069. Epub 2017 Mar 21.

PMID:
28257574
5.

Using natural products to promote caspase-8-dependent cancer cell death.

Tewary P, Gunatilaka AA, Sayers TJ.

Cancer Immunol Immunother. 2017 Feb;66(2):223-231. doi: 10.1007/s00262-016-1855-0. Epub 2016 Jun 10. Review.

PMID:
27286684
6.

Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.

Shanker A, Pellom ST Jr, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ.

Cancer Res. 2015 Dec 15;75(24):5260-72. doi: 10.1158/0008-5472.CAN-15-0794. Epub 2015 Oct 22.

7.

NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.

Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, Hagino T, Perez-Cunningham J, Sckisel GD, Urayama S, Monjazeb AM, Fragoso RC, Sayers TJ, Murphy WJ.

J Immunol. 2015 Oct 15;195(8):4010-9. doi: 10.4049/jimmunol.1500447. Epub 2015 Sep 11.

8.

Modulatory effects of bortezomib on host immune cell functions.

Pellom ST Jr, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A.

Immunotherapy. 2015;7(9):1011-22. doi: 10.2217/imt.15.66. Epub 2015 Sep 1. Review.

9.

Impact of dietary components on NK and Treg cell function for cancer prevention.

Kim YS, Sayers TJ, Colburn NH, Milner JA, Young HA.

Mol Carcinog. 2015 Sep;54(9):669-78. doi: 10.1002/mc.22301. Epub 2015 Apr 1. Review.

10.

Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation.

Henrich CJ, Brooks AD, Erickson KL, Thomas CL, Bokesch HR, Tewary P, Thompson CR, Pompei RJ, Gustafson KR, McMahon JB, Sayers TJ.

Cell Death Dis. 2015 Feb 26;6:e1666. doi: 10.1038/cddis.2015.38.

11.

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.

Canter RJ, Ames E, Mac S, Grossenbacher SK, Chen M, Li CS, Borys D, Smith RC, Tellez J, Sayers TJ, Monjazeb AM, Murphy WJ.

BMC Cancer. 2014 Oct 10;14:756. doi: 10.1186/1471-2407-14-756.

12.

Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.

Sayers KT, Brooks AD, Sayers TJ, Chertov O.

PLoS One. 2014 Aug 11;9(8):e104223. doi: 10.1371/journal.pone.0104223. eCollection 2014.

13.

Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.

Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH.

J Immunol. 2014 Jun 15;192(12):5821-9. doi: 10.4049/jimmunol.1400404. Epub 2014 May 7.

14.

A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells.

Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, Thomas CJ, de Kluyver RL, Sayers TJ, Ferrer M.

J Biomol Screen. 2012 Oct;17(9):1231-42. Epub 2012 Aug 27.

PMID:
22927676
15.

Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima.

Whitson EL, Sun H, Thomas CL, Henrich CJ, Sayers TJ, McMahon JB, Griesinger C, McKee TC.

J Nat Prod. 2012 Mar 23;75(3):394-9. doi: 10.1021/np200805z. Epub 2012 Feb 7.

16.

ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials.

Malyguine AM, Strobl S, Dunham K, Shurin MR, Sayers TJ.

Cells. 2012 May 10;1(2):111-26. doi: 10.3390/cells1020111.

17.

Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.

Henrich CJ, Thomas CL, Brooks AD, Booth NL, Lowery EM, Pompei RJ, McMahon JB, Sayers TJ.

Apoptosis. 2012 Jan;17(1):79-89. doi: 10.1007/s10495-011-0652-7.

18.

Targeting the extrinsic apoptosis signaling pathway for cancer therapy.

Sayers TJ.

Cancer Immunol Immunother. 2011 Aug;60(8):1173-80. doi: 10.1007/s00262-011-1008-4. Epub 2011 Apr 6. Review.

PMID:
21626033
19.

Clerodane diterpenes from Casearia arguta that act as synergistic TRAIL sensitizers.

Whitson EL, Thomas CL, Henrich CJ, Sayers TJ, McMahon JB, McKee TC.

J Nat Prod. 2010 Dec 27;73(12):2013-8. doi: 10.1021/np1004455. Epub 2010 Nov 10.

20.

Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.

Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP Jr.

Blood. 2010 Nov 18;116(20):4192-201. doi: 10.1182/blood-2010-02-271080. Epub 2010 Jul 29.

21.

New flow cytometric assays for monitoring cell-mediated cytotoxicity.

Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM.

Expert Rev Vaccines. 2010 Jun;9(6):601-16. doi: 10.1586/erv.10.49. Review.

22.

Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.

Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.

Mol Cancer Ther. 2010 Jun;9(6):1842-51. doi: 10.1158/1535-7163.MCT-09-0918. Epub 2010 Jun 1.

23.

Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.

Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ.

Mol Cancer Res. 2010 May;8(5):729-38. doi: 10.1158/1541-7786.MCR-10-0022. Epub 2010 May 4.

24.

Breast cancer bone metastases: combination therapy targeting cancer cells and the tumor microenvironment.

de Kluyver RL, Sayers TJ.

Cancer Biol Ther. 2010 Apr 1;9(7):551-3. Epub 2010 Apr 1. No abstract available.

PMID:
20234180
25.

Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.

Lee S, Yagita H, Sayers TJ, Celis E.

Cancer Immunol Immunother. 2010 Jul;59(7):1073-81. doi: 10.1007/s00262-010-0834-0. Epub 2010 Mar 6.

PMID:
20213120
26.

Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.

Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ.

Cancer Res. 2009 Aug 15;69(16):6615-23. doi: 10.1158/0008-5472.CAN-09-0685. Epub 2009 Aug 4.

27.

Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.

Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, Dai RM, Scheetz L, Lincoln E, Back TC, Powell D, Hurwitz AA, Sayers TJ, Kastelein R, Pavlakis GN, Felber BK, Trinchieri G, Wigginton JM.

J Immunol. 2009 Apr 1;182(7):4328-38. doi: 10.4049/jimmunol.0800471.

28.

A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.

Booth NL, Sayers TJ, Brooks AD, Thomas CL, Jacobsen K, Goncharova EI, McMahon JB, Henrich CJ.

Cancer Immunol Immunother. 2009 Aug;58(8):1229-44. doi: 10.1007/s00262-008-0637-8. Epub 2008 Dec 17.

29.

Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.

Sun K, Li M, Sayers TJ, Welniak LA, Murphy WJ.

Blood. 2008 Aug 15;112(4):1522-9. doi: 10.1182/blood-2008-03-143461. Epub 2008 Jun 6.

30.

Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.

Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.

J Natl Cancer Inst. 2008 May 7;100(9):649-62. doi: 10.1093/jnci/djn113. Epub 2008 Apr 29.

31.

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.

Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ.

J Immunol. 2008 Jan 1;180(1):163-70.

32.

NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.

Abdool K, Cretney E, Brooks AD, Kelly JM, Swann J, Shanker A, Bere EW Jr, Yokoyama WM, Ortaldo JR, Smyth MJ, Sayers TJ.

J Immunol. 2006 Aug 15;177(4):2575-83.

33.

Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.

Khan T, Stauffer JK, Williams R, Hixon JA, Salcedo R, Lincoln E, Back TC, Powell D, Lockett S, Arnold AC, Sayers TJ, Wigginton JM.

J Immunol. 2006 May 15;176(10):6302-12.

34.

TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.

Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ.

Immunol Cell Biol. 2006 Feb;84(1):87-98. Review. Erratum in: Immunol Cell Biol. 2006 Apr;84(2):238.

PMID:
16405656
35.

The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.

Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, Sayers TJ.

Ann N Y Acad Sci. 2005 Nov;1059:160-7.

PMID:
16382051
36.

Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L.

Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ, Wiltrout RH.

Cell Immunol. 2005 Jun;235(2):145-52. Epub 2005 Oct 6.

PMID:
16213477
37.

Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.

Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR, Welniak LA, Murphy WJ.

Blood. 2005 Nov 1;106(9):3293-9. Epub 2005 Jun 16.

38.

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.

Sayers TJ, Murphy WJ.

Cancer Immunol Immunother. 2006 Jan;55(1):76-84. Epub 2005 Oct 27. Review.

PMID:
15864587
39.

Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis.

Brooks AD, Sayers TJ.

Cancer Immunol Immunother. 2005 May;54(5):499-505. Epub 2004 Dec 22.

PMID:
15614529
40.

NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.

Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y.

J Exp Med. 2004 Nov 15;200(10):1325-35.

41.

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ.

Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5. Epub 2004 May 17. Erratum in: Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12777.

42.

Discordant regulation of granzyme H and granzyme B expression in human lymphocytes.

Sedelies KA, Sayers TJ, Edwards KM, Chen W, Pellicci DG, Godfrey DI, Trapani JA.

J Biol Chem. 2004 Jun 18;279(25):26581-7. Epub 2004 Apr 6.

43.

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ.

J Exp Med. 2004 Feb 16;199(4):437-48. Epub 2004 Feb 9.

44.

Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer.

Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH.

Apoptosis. 2003 Mar;8(2):151-60.

PMID:
12766475
45.

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ.

Blood. 2003 Jul 1;102(1):303-10. Epub 2003 Mar 13.

PMID:
12637321
46.

Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.

Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH.

J Immunol. 2003 Mar 1;170(5):2727-33.

47.

Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.

Komatsu M, Mammolenti M, Jones M, Jurecic R, Sayers TJ, Levy RB.

Blood. 2003 May 15;101(10):3991-9. Epub 2003 Jan 9.

PMID:
12521999
48.

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.

Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ.

Cancer Res. 2003 Jan 1;63(1):207-13.

49.

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.

J Immunol. 2002 Apr 1;168(7):3484-92.

50.

Unlocking the secrets of cytotoxic granule proteins.

Smyth MJ, Kelly JM, Sutton VR, Davis JE, Browne KA, Sayers TJ, Trapani JA.

J Leukoc Biol. 2001 Jul;70(1):18-29. Review.

PMID:
11435481

Supplemental Content

Loading ...
Support Center